Quest Offers Septin9 Colorectal Cancer Assay — a Little Later Than Originally Planned

The test, which Quest markets as ColoVantage, was originally slated to debut last year. The launch makes Quest the first commercial lab in the US to offer a lab-developed test based on Epigenomics' Septin9 biomarker.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.